MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
27.43
+1.10
+4.18%
After Hours: 27.59 +0.16 +0.58% 19:58 04/10 EDT
OPEN
26.49
PREV CLOSE
26.33
HIGH
27.48
LOW
25.79
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
36.44
52 WEEK LOW
13.53
MARKET CAP
2.79B
P/E (TTM)
-33.9144
1D
5D
1M
3M
1Y
5Y
1D
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
The Motley Fool · 1d ago
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
TipRanks · 2d ago
JonesTrading Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
TipRanks · 6d ago
Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication
Simply Wall St · 6d ago
Weekly Report: what happened at BEAM last week (0330-0403)?
Weekly Report · 6d ago
Assessing Beam Therapeutics (BEAM) Valuation After Major BEACON Trial Milestone For Sickle Cell Therapy
Simply Wall St · 04/04 06:24
Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Seeking Alpha · 04/03 18:25
Beam Therapeutics CEO John M. Evans disposes of $1.1 million common shares
Reuters · 04/01 22:32
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.